Ascend Performance Materials, S Group Partner To Commercialise Acteev Protect Textiles

Company Performance

Ascend Performance Materials, S Group Partner To Commercialise Acteev Protect Textiles

Ascend Performance Materials has announced a commercial agreement with The S Group, a globally recognised provider of apparel design, development and manufacturing. The alliance will focus on commercialisation of Acteev Protect antimicrobial yarns, fibres and fabrics, offering customers full-scale supply chain service from garment design to delivery. The agreement pairs Ascend's world-class manufacturing operations with The S Group's track record of success in the wholesale and direct-to-consumer apparel industry, Ascend reports. "Our customers will now benefit from a revolutionary antimicrobial material combined with end-to-end support to guide a product from ideation to actualisation," said Lu Zhang, vice president of Acteev. The S Group offers complete supply chain management for apparel brands, including product development, manufacturing, logistics, quality assurance, packaging and order fulfillment. The company lists some of the world's most recognised brands among its partners, including Lululemon, New Balance and Mack Weldon. Athleisure, performance, scrubs, and seamless products such as intimates, leggings, active wear, socks and gaiters will be available. Acteev is Ascend's patent-pending technology that embeds zinc ions in a polymer to create fibres with long-lasting antimicrobial properties. The result is a fabric that destroys odour-causing bacteria and fungi. Acteev technology is available in a wide range of textiles featuring the flexibility, softness and durability of nylon 6.6. According to Ascend, recent testing on knit fabric completed at the University of Cambridge has demonstrated that Acteev technology deactivates the virus SARS-CoV-2, with 99.9% efficacy on contact. Ascend is working with the US Environmental Protection Agency, the US Food and Drug Administration and other governmental agencies to obtain the appropriate regulatory clearances to make specific claims regarding the technology's antiviral properties.